ATE76311T1
(de)
|
1986-08-19 |
1992-06-15 |
Genentech Inc |
Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US5661125A
(en)
*
|
1992-08-06 |
1997-08-26 |
Amgen, Inc. |
Stable and preserved erythropoietin compositions
|
US6012450A
(en)
*
|
1993-01-29 |
2000-01-11 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
PL179443B1
(pl)
|
1994-03-07 |
2000-09-29 |
Inhale Therapeutic Syst |
Kompozycja insuliny, sposób wytwarzania kompozycji insuliny i sposób wytwarzania dawki insuliny w postaci aerozolu PL PL PL PL
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
ES2245780T3
(es)
|
1994-05-18 |
2006-01-16 |
Nektar Therapeutics |
Metodos y composiciones para la formulacion de interferones como un polvo seco.
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
IL116085A
(en)
*
|
1994-12-16 |
1999-12-31 |
Ortho Pharma Corp |
Spray dried erythropoietin
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
EP0817655B1
(de)
*
|
1995-03-31 |
2004-05-19 |
Aradigm Corporation |
Intrapulmonare verabreichung vom hematopoietischem medikament
|
KR19980703876A
(ko)
*
|
1995-04-14 |
1998-12-05 |
스티븐 엘. 허스트 |
분산성이 개선된 분말화된 약학적 조성물
|
EP1961760A3
(de)
|
1995-06-07 |
2008-09-03 |
Glaxo Group Limited |
Peptide und Verbindungen, die einen Thrombopoietin-Rezeptor binden
|
US5869451A
(en)
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
DE19539574A1
(de)
*
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
NZ332669A
(en)
*
|
1996-04-29 |
1999-02-25 |
Dura Pharma Inc |
A dry power inhalation system which is flow rate independent
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
GB9612297D0
(en)
*
|
1996-06-11 |
1996-08-14 |
Minnesota Mining & Mfg |
Medicinal aerosol formulations
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
DE19733651A1
(de)
*
|
1997-08-04 |
1999-02-18 |
Boehringer Ingelheim Pharma |
Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
SK285068B6
(sk)
†
|
1997-09-29 |
2006-05-04 |
Nektar Therapeutics |
Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
WO1999054486A1
(en)
*
|
1998-04-22 |
1999-10-28 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
BR0010316A
(pt)
*
|
1999-05-11 |
2004-04-27 |
Ortho Mcnell Pharmaceutical In |
Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
|
US7668658B2
(en)
|
1999-10-13 |
2010-02-23 |
Sequenom, Inc. |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
KR20020056923A
(ko)
|
1999-11-18 |
2002-07-10 |
코르바스 인터내셔날, 인코포레이티드 |
엔도텔리아제를 암호화하는 핵산, 엔도텔리아제 및 이의용도
|
EP1244432A2
(de)
*
|
1999-12-30 |
2002-10-02 |
Chiron Corporation |
Verfahren zur pulmonaren verabreichung von interleukin-2
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
DK1280520T4
(en)
|
2000-05-10 |
2018-06-25 |
Novartis Ag |
Phospholipid based powders for drug delivery
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
ES2237574T5
(es)
*
|
2000-05-15 |
2017-08-09 |
F. Hoffmann-La Roche Ag |
Composición farmacéutica líquida que contiene un derivado de eritropoyetina
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
US20040109827A1
(en)
*
|
2000-11-29 |
2004-06-10 |
Satomi Onoue |
Powdery preparations and proecss for producing the same
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
MXPA03006952A
(es)
*
|
2001-02-02 |
2004-10-15 |
Johnson & Johnson |
Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
|
US20030072717A1
(en)
*
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
WO2002072786A2
(en)
|
2001-03-13 |
2002-09-19 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
US20030064052A1
(en)
*
|
2001-05-21 |
2003-04-03 |
Ponwell Enterprises, Ltd. |
Compositions for protein delivery via the pulmonary route
|
EG24184A
(en)
*
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
EP1458360B1
(de)
|
2001-12-19 |
2011-05-11 |
Novartis AG |
Pulmonale verabreichung von aminoglykosiden
|
AU2002351746A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Maxygen Aps |
Erythropoietin conjugates
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
WO2003093296A2
(en)
|
2002-05-03 |
2003-11-13 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US20040009908A1
(en)
*
|
2002-07-10 |
2004-01-15 |
Stamler Jonathan S. |
Methods for treating or preventing ischemic injury
|
DE10234192B4
(de)
*
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
DK1542714T3
(da)
|
2002-09-18 |
2014-05-26 |
Janssen Pharmaceuticals Inc |
Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
|
EP1852441B1
(de)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Mittel zur Modulierung der EPH-Rezeptor-Aktivität
|
US7923032B2
(en)
*
|
2002-11-26 |
2011-04-12 |
Seacoast Neuroscience, Inc. |
Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
|
US20040132645A1
(en)
*
|
2003-01-03 |
2004-07-08 |
Knox Susan J. |
Methods for modulating effects of radiation in a subject
|
CA2833559A1
(en)
|
2003-02-14 |
2004-09-02 |
Children's Hospital & Research Center At Oakland |
Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
DE102004063927A1
(de)
*
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
EP1848461A2
(de)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Konjugate einer epo-gruppierung und eines polymers
|
US7827042B2
(en)
|
2005-11-30 |
2010-11-02 |
The Invention Science Fund I, Inc |
Methods and systems related to transmission of nutraceutical associated information
|
US8297028B2
(en)
|
2006-06-14 |
2012-10-30 |
The Invention Science Fund I, Llc |
Individualized pharmaceutical selection and packaging
|
US8068991B2
(en)
|
2005-11-30 |
2011-11-29 |
The Invention Science Fund I, Llc |
Systems and methods for transmitting pathogen related information and responding
|
US8000981B2
(en)
|
2005-11-30 |
2011-08-16 |
The Invention Science Fund I, Llc |
Methods and systems related to receiving nutraceutical associated information
|
US8340944B2
(en)
|
2005-11-30 |
2012-12-25 |
The Invention Science Fund I, Llc |
Computational and/or control systems and methods related to nutraceutical agent selection and dosing
|
US10296720B2
(en)
|
2005-11-30 |
2019-05-21 |
Gearbox Llc |
Computational systems and methods related to nutraceuticals
|
US7927787B2
(en)
|
2006-06-28 |
2011-04-19 |
The Invention Science Fund I, Llc |
Methods and systems for analysis of nutraceutical associated components
|
US7974856B2
(en)
|
2005-11-30 |
2011-07-05 |
The Invention Science Fund I, Llc |
Computational systems and methods related to nutraceuticals
|
AR060522A1
(es)
*
|
2006-04-19 |
2008-06-25 |
Alba Therapeutics Corp |
Uso de agonistas de uniones apretadas para facilitar la entrega pulmonar de agentes terapeuticos
|
KR20150033726A
(ko)
|
2006-07-05 |
2015-04-01 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
KR20150041804A
(ko)
|
2007-02-11 |
2015-04-17 |
맵 파마슈티컬스, 인코포레이티드 |
부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 dhe의 치료적 투여 방법
|
PL2340031T4
(pl)
|
2008-08-14 |
2020-12-28 |
Acceleron Pharma Inc. |
Zastosowanie pułapek GDF do leczenia niedokrwistości
|
CA2767773C
(en)
|
2011-02-11 |
2015-11-24 |
Grain Processing Corporation |
Composition comprising a salt and a crystallization interrupter
|
EP3875104A1
(de)
*
|
2011-10-17 |
2021-09-08 |
Acceleron Pharma Inc. |
Zusammensetzungen zur behandlung von myelofibrose
|
CN108997490A
(zh)
|
2012-01-26 |
2018-12-14 |
克里斯托弗·J·索尔斯 |
肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
US10105410B2
(en)
|
2014-03-10 |
2018-10-23 |
Rambam Med-Tech Ltd. |
Heparanase inhibitory peptides and use thereof for treating clinical pathologies
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
EP4316595A3
(de)
|
2016-09-02 |
2024-04-17 |
Christopher J. Soares |
Verwendung von cgrp-rezeptor-antagonisten bei der behandlung des glaukoms
|
CA3070442A1
(en)
|
2017-07-26 |
2019-01-31 |
Janssen Pharmaceutica Nv |
Methods of protecting vascular integrity induced by targeted radiation therapy
|
CN113766926A
(zh)
|
2019-01-25 |
2021-12-07 |
詹森药业有限公司 |
与放射和/或放射模拟物治疗结合的减轻肝损伤和促进肝肥大、再生和细胞植入的方法
|
US20200237872A1
(en)
|
2019-01-25 |
2020-07-30 |
Janssen Pharmaceutica Nv |
Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
|
CN113905754A
(zh)
|
2019-01-25 |
2022-01-07 |
詹森药业有限公司 |
减轻起疱剂和腐蚀性气体毒性作用的方法
|
JP2022526367A
(ja)
|
2019-03-29 |
2022-05-24 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
リポカリンムテインの吸入投与
|
AU2020322107A1
(en)
|
2019-08-01 |
2022-02-03 |
Acm Biolabs Pte Ltd |
A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
|
WO2021214339A2
(en)
|
2020-04-24 |
2021-10-28 |
Acm Biolabs Pte Ltd |
Vaccine against human-pathogenic coronaviruses
|
AU2021396659A1
(en)
|
2020-12-11 |
2023-05-04 |
Acm Biolabs Pte Ltd |
Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
|
US20240108720A1
(en)
|
2021-02-02 |
2024-04-04 |
Acm Biolabs Pte Ltd |
Sole use of polymersome associated adjuvant for stimulating an immune response
|
US20240228562A1
(en)
|
2021-04-08 |
2024-07-11 |
Pieris Pharmaceuticals Gmbh |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
IL311797A
(en)
|
2021-10-01 |
2024-05-01 |
Albert Einstein College Of Medicine |
Methods for increasing stem cell production
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2024186690A2
(en)
|
2023-03-03 |
2024-09-12 |
Enosi Therapeutics Corporation |
Oligo-trap fusion proteins (ofps) and uses thereof
|